Gleevec/imatinib, an ABL2 kinase inhibitor, protects tumor and endothelial cells from semaphorin-induced cytoskeleton collapse and loss of cell motility
Keywords: SEMA3A&F; semaphorin 3A and 3F; EC; endothelial cell; HUVEC; human umbilical vein endothelial cell; NRP; neuropilin; PDGFR; platelet-derived growth factor receptor; VEGFR; vascular endothelial growth factor receptor; SICHI; semaphorin induced chemorepulsi